Chart Events
Performance Outlook
| Previous Close | 138.08 |
| Open | 138.02 |
| Bid | 138.78 x 800 |
| Ask | 138.80 x 1000 |
| Day's Range | 137.65 - 139.08 |
| 52 Week Range | 130.96 - 168.11 |
| Volume | |
| Avg. Volume | 4,788,853 |
| Market Cap | 244.989B |
| Beta (5Y Monthly) | 0.48 |
| PE Ratio (TTM) | 38.02 |
| EPS (TTM) | 3.65 |
| Earnings Date | Feb 07, 2024 - Feb 12, 2024 |
| Forward Dividend & Yield | 6.20 (4.49%) |
| Ex-Dividend Date | Jan 12, 2024 |
| 1y Target Est | 169.72 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ABBV
Related Research
- AbbVie Inc.Analyst Report: AbbVie IncAbbVie, a research-based biopharmaceutical company, was spun off from Abbott Laboratories in January 2013. The company is based in suburban Chicago. The shares are a component of the S&P 500.RatingFair ValueEconomic Moat26 days agoArgus Research
Zacks4 Large Drug Stocks to Watch as IBD Market Gains Traction
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
- PR Newswire
AbbVie Announces Positive Topline Results from Phase 2 LUMINOSITY Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC)
AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The results demonstrated a compelling overall response rate per independent central review (ICR) of 35 percent and 23 percent across c-Met High and c-Met Intermediate patients respectively.
Simply Wall St.AbbVie (NYSE:ABBV) Has Announced That It Will Be Increasing Its Dividend To $1.55
AbbVie Inc. ( NYSE:ABBV ) has announced that it will be increasing its dividend from last year's comparable payment on...
